{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:33:30Z","timestamp":1790436810132,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Mirikizumab has demonstrated efficacy in moderately to severely active ulcerative colitis. A 1\u20132-point change in Urgency Numeric Rating Scale (NRS) score can be meaningful for patients. In these post-hoc analyses, we evaluated the efficacy of mirikizumab compared to placebo by baseline Urgency NRS score groups (0\u20133, 4\u20136, and 7\u201310) and its effect on bowel urgency severity over time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methodology<\/jats:title>\n            <jats:p>Urgency NRS was measured as a secondary outcome at baseline, week 12, and week 52. Bowel urgency improvement was assessed for patients who achieved and did not achieve multiple efficacy endpoints. Data were analyzed using Fisher\u2019s exact test with nonresponder imputation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At weeks 12 and 52, a significantly higher percentage of mirikizumab-treated patients achieved clinical response as well as clinical, endoscopic, and symptomatic remission compared to placebo-treated patients, regardless of baseline Urgency NRS score category (higher proportions versus placebo, delta 9%\u201345%). Improvement in Urgency NRS score category at weeks 12 and 52 for mirikizumab-treated patients was observed when other efficacy outcomes were achieved (13%\u201390%) and not achieved (12%\u201375%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A greater proportion of mirikizumab-treated patients with ulcerative colitis achieved symptomatic, clinical, and endoscopic remission endpoints compared to placebo-treated patients, regardless of baseline bowel urgency severity. After one year, bowel urgency was improved to a greater extent with mirikizumab than with placebo, even for patients who did not achieve other clinical outcomes. Small improvements in bowel urgency are associated with significant health-related quality-of-life improvements. Monitoring shifts in urgency severity over time using the Urgency NRS can aid in understanding patients\u2019 treatment outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>LUCENT-1 (NCT03518086) Registered 04 May 2018 <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03518086\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03518086<\/jats:ext-link>. LUCENT-2 (NCT03524092) Registered 10 May 2018 <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03524092\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03524092<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41687-025-00906-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:14:25Z","timestamp":1751357665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab"],"prefix":"10.1186","volume":"9","author":[{"given":"David B.","family":"Clemow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C.","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin K.","family":"Baygani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Keohane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa Hunter","family":"Gibble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P. L.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"906_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s41687-019-0154-x","volume":"3","author":"L Newton","year":"2019","unstructured":"Newton L, Randall JA, Hunter T, Keith S, Symonds T, Secrest RJ, et al (2019) A qualitative study exploring the health-related quality of life and symptomatic experiences of adults and adolescents with ulcerative colitis. J Patient Rep Outcomes 3(1):66. https:\/\/doi.org\/10.1186\/s41687-019-0154-x","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"906_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12876-019-0963-7","volume":"19","author":"BK Perler","year":"2019","unstructured":"Perler BK, Ungaro R, Baird G, Mallette M, Bright R, Shah S, et al (2019) Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. BMC Gastroenterol 19(1):47. https:\/\/doi.org\/10.1186\/s12876-019-0963-7","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"906_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","volume":"13","author":"E Louis","year":"2020","unstructured":"Louis E, Ramos-Goni JM, Cuervo J, Kopylov U, Barreiro-de Acosta M, McCartney S, et al (2020) A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective. Patient 13(3):317\u2013325. https:\/\/doi.org\/10.1007\/s40271-019-00407-5","journal-title":"Patient"},{"issue":"12","key":"906_CR4","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1007\/s11136-020-02606-2","volume":"29","author":"WK van Deen","year":"2020","unstructured":"van Deen WK, Obremskey A, Moore G, van den Akker-van MME, Doctor JN, Hwang C (2020) An assessment of symptom burden in inflammatory bowel diseases to develop a patient preference-weighted symptom score. Qual Life Res 29(12):3387\u20133396. https:\/\/doi.org\/10.1007\/s11136-020-02606-2","journal-title":"Qual Life Res"},{"issue":"3","key":"906_CR5","doi-asserted-by":"publisher","first-page":"otab050","DOI":"10.1093\/crocol\/otab050","volume":"3","author":"N Teich","year":"2021","unstructured":"Teich N, Schulze H, Knop J, Obermeier M, Stallmach A (2021) Novel approaches identifying relevant patient-reported outcomes in patients with inflammatory bowel diseases-listen 1. CC360 3(3):otab050. https:\/\/doi.org\/10.1093\/crocol\/otab050","journal-title":"CC360"},{"issue":"9","key":"906_CR6","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/MEG.0000000000000658","volume":"28","author":"D Carpio","year":"2016","unstructured":"Carpio D, Lopez-Sanroman A, Calvet X, Romero C, Cea-Calvo L, Julia B, Arguelles-Arias F (2016) Perception of disease burden and treatment satisfaction in patients with ulcerative colitis from outpatient clinics in Spain: UC-LIFE survey. Eur J Gastroenterol Hepatol 28(9):1056\u20131064. https:\/\/doi.org\/10.1097\/MEG.0000000000000658","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"906_CR7","doi-asserted-by":"publisher","first-page":"otab046","DOI":"10.1093\/crocol\/otab046","volume":"3","author":"GK Dawwas","year":"2021","unstructured":"Dawwas GK, Jajeh H, Shan M, Naegeli AN, Hunter T, Lewis JD (2021) Prevalence and factors associated with fecal urgency among patients with ulcerative colitis and crohn\u2019s disease in the study of a prospective adult research cohort with inflammatory bowel disease. CC360 3(3):otab046. https:\/\/doi.org\/10.1093\/crocol\/otab046","journal-title":"CC360"},{"issue":"1","key":"906_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000505092","volume":"5","author":"T Hibi","year":"2020","unstructured":"Hibi T, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T (2020) Ulcerative colitis: disease burden, impact on daily life, and reluctance to consult medical professionals: results from a Japanese internet survey. Inflamm Intest Dis 5(1):27\u201335. https:\/\/doi.org\/10.1159\/000505092","journal-title":"Inflamm Intest Dis"},{"issue":"11","key":"906_CR9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/ibd\/izab016","volume":"27","author":"MC Dubinsky","year":"2021","unstructured":"Dubinsky MC, Watanabe K, Molander P, Peyrin-Biroulet L, Rubin M, Melmed GY, et al (2021) Ulcerative colitis narrative global survey findings: the impact of living with ulcerative colitis-patients\u2019 and physicians\u2019 view. Inflamm Bowel Dis 27(11):1747\u20131755. https:\/\/doi.org\/10.1093\/ibd\/izab016","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"906_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","volume":"49","author":"F Casellas","year":"2017","unstructured":"Casellas F, Herrera-de Guise C, Robles V, Navarro E, Borruel N (2017) Patient preferences for inflammatory bowel disease treatment objectives. Dig Liver Dis 49(2):152\u2013156. https:\/\/doi.org\/10.1016\/j.dld.2016.09.009","journal-title":"Dig Liver Dis"},{"issue":"4","key":"906_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/jan.13492","volume":"74","author":"L Dibley","year":"2018","unstructured":"Dibley L, Norton C, Whitehead E (2018) The experience of stigma in inflammatory bowel disease: an interpretive (hermeneutic) phenomenological study. J Adv Nurs 74(4):838\u2013851. https:\/\/doi.org\/10.1111\/jan.13492","journal-title":"J Adv Nurs"},{"issue":"8","key":"906_CR12","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/j.crohns.2012.11.004","volume":"7","author":"C Norton","year":"2013","unstructured":"Norton C, Dibley LB, Bassett P (2013) Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohns Colitis 7(8):e302\u201311. https:\/\/doi.org\/10.1016\/j.crohns.2012.11.004","journal-title":"J Crohns Colitis"},{"issue":"12","key":"906_CR13","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1097\/MIB.0000000000000962","volume":"22","author":"GA Tew","year":"2016","unstructured":"Tew GA, Jones K, Mikocka-Walus A (2016) Physical activity habits, limitations, and predictors in people with inflammatory bowel disease: a large cross-sectional online survey. Inflamm Bowel Dis 22(12):2933\u20132942. https:\/\/doi.org\/10.1097\/MIB.0000000000000962","journal-title":"Inflamm Bowel Dis"},{"key":"906_CR14","doi-asserted-by":"publisher","unstructured":"Travis S, Potts Bleakman A, Dubinsky MC, Schreiber S, Panaccione R, Hibi T, et al (2023) The communicating needs and features of ibd experiences (confide) study: US and European patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izad142","DOI":"10.1093\/ibd\/izad142"},{"issue":"1","key":"906_CR15","doi-asserted-by":"publisher","first-page":"otac044","DOI":"10.1093\/crocol\/otac044","volume":"5","author":"MC Dubinsky","year":"2023","unstructured":"Dubinsky MC, Clemow DB, Hunter Gibble T, Li X, Vermeire S, Hisamatsu T, Travis SPL (2023) Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission. CC360 5(1):otac044. https:\/\/doi.org\/10.1093\/crocol\/otac044","journal-title":"CC360"},{"issue":"1","key":"906_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s41687-022-00522-2","volume":"6","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Shan M, Delbecque L, Lissoos T, Hunter T, Harding G, et al (2022) Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis. J Patient Rep Outcomes 6(1):114. https:\/\/doi.org\/10.1186\/s41687-022-00522-2","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"906_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","volume":"6","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Irving PM, Panaccione R, Naegeli AN, Potts-Bleakman A, Arora V, et al (2022) Incorporating patient experience into drug development for ulcerative colitis: development of the urgency numeric rating scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes 6(1):31. https:\/\/doi.org\/10.1186\/s41687-022-00439-w","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"906_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","volume":"162","author":"BE Sands","year":"2022","unstructured":"Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, et al (2022) Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease. Gastroenterology 162(2):495\u2013508. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.050","journal-title":"Gastroenterology"},{"key":"906_CR19","unstructured":"OMVOH\u2122 prescribing information. In: ELa C, editor. 2023."},{"issue":"26","key":"906_CR20","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al (2023) Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 388(26):2444\u20132455. https:\/\/doi.org\/10.1056\/NEJMoa2207940","journal-title":"N Engl J Med"},{"key":"906_CR21","doi-asserted-by":"publisher","unstructured":"Public Policy Committee ISoP (2016) Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 25(1):2\u201310. https:\/\/doi.org\/10.1002\/pds.3891","DOI":"10.1002\/pds.3891"},{"issue":"12","key":"906_CR22","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1007\/s11136-023-03494-y","volume":"32","author":"MC Dubinsky","year":"2023","unstructured":"Dubinsky MC, Delbecque L, Hunter T, Harding G, Stassek L, Moses RE, Lewis JD (2023) Validation of the bowel urgency numeric rating scale in patients with Crohn\u2019s disease: results from a mixed methods study. Qual Life Res 32(12):3403\u20133415. https:\/\/doi.org\/10.1007\/s11136-023-03494-y","journal-title":"Qual Life Res"},{"issue":"3","key":"906_CR23","doi-asserted-by":"publisher","first-page":"otac016","DOI":"10.1093\/crocol\/otac016","volume":"4","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Panaccione R, Lewis JD, Sands BE, Hibi T, Lee SD, et al (2022) Impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis. CC360 4(3):otac016. https:\/\/doi.org\/10.1093\/crocol\/otac016","journal-title":"CC360"},{"issue":"5","key":"906_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"MF Neurath","year":"2014","unstructured":"Neurath MF (2014) Cytokines in inflammatory bowel disease. Nat Rev Immunol 14(5):329\u2013342. https:\/\/doi.org\/10.1038\/nri3661","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"906_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/gastro\/gou031","volume":"2","author":"TC DeRoche","year":"2014","unstructured":"DeRoche TC, Xiao SY, Liu X (2014) Histological evaluation in ulcerative colitis. Gastroenterol Rep (Oxf) 2(3):178\u2013192. https:\/\/doi.org\/10.1093\/gastro\/gou031","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"1","key":"906_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/j.gastro.2021.09.052","volume":"162","author":"N Krugliak Cleveland","year":"2022","unstructured":"Krugliak Cleveland N, Rai V, El Jurdi K, Rao SS, Giurcanu MC, Rubin DT (2022) Ulcerative colitis patients have reduced rectal compliance compared with non-inflammatory bowel disease controls. Gastroenterology 162(1):331\u20133e1. https:\/\/doi.org\/10.1053\/j.gastro.2021.09.052","journal-title":"Gastroenterology"},{"issue":"3","key":"906_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/gut.29.3.342","volume":"29","author":"SS Rao","year":"1988","unstructured":"Rao SS, Holdsworth CD, Read NW (1988) Symptoms and stool patterns in patients with ulcerative colitis. Gut 29(3):342\u2013345. https:\/\/doi.org\/10.1136\/gut.29.3.342","journal-title":"Gut"},{"issue":"6","key":"906_CR28","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/0016-5085(87)90255-1","volume":"93","author":"SS Rao","year":"1987","unstructured":"Rao SS, Read NW, Davison PA, Bannister JJ, Holdsworth CD (1987) Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology 93(6):1270\u20131275. https:\/\/doi.org\/10.1016\/0016-5085(87)90255-1","journal-title":"Gastroenterology"},{"issue":"4","key":"906_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/01.MIB.0000209365.09189.04","volume":"12","author":"AM Drewes","year":"2006","unstructured":"Drewes AM, Frokjaer JB, Larsen E, Reddy H, Arendt-Nielsen L, Gregersen H (2006) Pain and mechanical properties of the rectum in patients with active ulcerative colitis. Inflamm Bowel Dis 12(4):294\u2013303. https:\/\/doi.org\/10.1097\/01.MIB.0000209365.09189.04","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"906_CR30","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/apt.14526","volume":"47","author":"IO Gordon","year":"2018","unstructured":"Gordon IO, Agrawal N, Willis E, Goldblum JR, Lopez R, Allende D, et al (2018) Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther 47(7):922\u2013939. https:\/\/doi.org\/10.1111\/apt.14526","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"906_CR31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/MEG.0b013e328326cacb","volume":"21","author":"AK Waljee","year":"2009","unstructured":"Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD (2009) Patient reported symptoms during an ulcerative colitis flare: a qualitative focus group study. Eur J Gastroenterol Hepatol 21(5):558\u2013564. https:\/\/doi.org\/10.1097\/MEG.0b013e328326cacb","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"906_CR32","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1097\/MIB.0000000000000834","volume":"22","author":"JK Limdi","year":"2016","unstructured":"Limdi JK (2016) Rectal therapy in ulcerative colitis: science and sensitivity. Inflamm Bowel Dis 22(7):E24\u20135. https:\/\/doi.org\/10.1097\/MIB.0000000000000834","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"906_CR33","doi-asserted-by":"publisher","first-page":"e00578","DOI":"10.14309\/ctg.0000000000000578","volume":"14","author":"B Steere","year":"2023","unstructured":"Steere B, Schmitz J, Powell N, Higgs R, Gottlieb K, Liu Y, et al (2023) Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-tnf resistance: results from a phase 2 Study. Clin Transl Gastroenterol 14(7):e00578. https:\/\/doi.org\/10.14309\/ctg.0000000000000578","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"906_CR34","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/ibd\/izaa045","volume":"26","author":"GT Ho","year":"2020","unstructured":"Ho GT, Cartwright JA, Thompson EJ, Bain CC, Rossi AG (2020) Resolution of inflammation and gut repair in ibd: translational steps towards complete mucosal healing. Inflamm Bowel Dis 26(8):1131\u20131143. https:\/\/doi.org\/10.1093\/ibd\/izaa045","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"906_CR35","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","volume":"62","author":"L Chua","year":"2023","unstructured":"Chua L, Friedrich S, Zhang XC (2023) Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase III LUCENT studies. Clin Pharmacokinet 62(10):1479\u20131491. https:\/\/doi.org\/10.1007\/s40262-023-01281-z","journal-title":"Clin Pharmacokinet"},{"key":"906_CR36","doi-asserted-by":"publisher","unstructured":"Sands BE, D\u2019Haens G, Clemow DB, Irving PM, Johns JT, Hunter GT, et al (2024) Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension Study. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izae024","DOI":"10.1093\/ibd\/izae024"},{"issue":"5","key":"906_CR37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/ecco-jcc\/jjy196","volume":"13","author":"MJ de Jong","year":"2019","unstructured":"de Jong MJ, Roosen D, Degens J, van den Heuvel TRA, Romberg-Camps M, Hameeteman W, et al (2019) Development and validation of a patient-reported score to screen for mucosal inflammation in inflammatory bowel disease. J Crohns Colitis 13(5):555\u2013563. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy196","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"906_CR38","doi-asserted-by":"publisher","first-page":"i2057","DOI":"10.1093\/ecco-jcc\/jjae190.1296","volume":"19","author":"SW Schreiber","year":"2025","unstructured":"Schreiber SW, Clemow DB, Yu G, Keefer LA, Ananthakrishnan AN, D\u2019Haens G, et al (2025) P1122 Identification of responder subpopulations in moderately-to-severely active Crohn\u2019s disease patients treated with mirikizumab: results from the VIVID-1 study. J Crohns Colitis 19(Supplement_1):i2057\u2013i8. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.1296","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"906_CR39","doi-asserted-by":"publisher","first-page":"i1950","DOI":"10.1093\/ecco-jcc\/jjae190.1232","volume":"19","author":"SW Schreiber","year":"2025","unstructured":"Schreiber SW, Clemow DB, Yu G, Keefer LA, Ananthakrishnan AN, D\u2019Haens G, et al (2025) P1058 Trajectories of response in patients with moderately-to-severely active Crohn\u2019s disease treated with mirikizumab based on biofailed status: post hoc results from the VIVID-1 study. J Crohns Colitis 19(Supplement_1):i1950\u2013i1. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.1232","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"906_CR40","doi-asserted-by":"publisher","first-page":"i1592","DOI":"10.1093\/ecco-jcc\/jjae190.1007","volume":"19","author":"SW Schreiber","year":"2025","unstructured":"Schreiber SW, Clemow DB, Yu G, Keefer LA, Ananthakrishnan AN, D\u2019Haens G, et al (2025) P0833 Trajectories of response in patients with moderately-to-severely active Crohn\u2019s disease treated with mirikizumab or ustekinumab: post hoc results from the VIVID-1 study. J Crohns Colitis 19(Supplement_1):i1592\u2013i4. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.1007","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00906-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:14:29Z","timestamp":1751357669000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-025-00906-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00906-0","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants included in these studies. This study was performed in compliance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines. Approval was granted by the ethics board that reviewed the study at each site level for each study (LUCENT-1 (NCT03518086); LUCENT-2 (NCT03524092)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.B.C., SK.B., T.H.G., and R.E.M. are employees and stockholders of Eli Lilly and Company. M.C.D. reports consulting fees from AbbVie, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche, Genentech (Roche), Gilead Sciences, Janssen, Pfizer, Prometheus Biosciences, Takeda, and UCB; contracted research from AbbVie and Janssen; stock interest in Trellus Health; and licensing fees from Takeda. B.E.S. reports consulting fees from AbbVie, Alimentiv, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Biora Therapeutics, Inc., Boehringer Ingelheim, Boston Pharmaceuticals, Calibr, Celgene, Celltrion, ClostraBio, Enthera, Equillium, Evommune, Fresenius Kabi, Galapagos, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Kaleido Biosciences, Kallyope, Merck & Co., Morphic Therapeutic, MRM Health, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Sun Pharma, Surrozen, Target RWE, Teva Pharmaceuticals, TLL Pharmaceuticals LLC, and Ventyx Biosciences; consulting and speaking fees from Abivax; consulting and speaking fees and other support from Eli Lilly and Company; research grants, consulting and speaking fees, and other support from Bristol Myers Squibb, Janssen, Pfizer, and Takeda; research grants and consulting fees from Theravance Biopharma; and stock options from Ventyx Biosciences. A.K. is an employee of HaaPACS GmbH, Statistics, Germany, and reports being a contractor for Eli Lilly and Company. S.D. reports consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly and Company, Enthera, Ferring Pharmaceuticals, Gilead Sciences, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB, and Vifor. S.S. reports personal fees for consulting in advisory boards from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Ferring, Fresenius, Galapagos, Gilead Sciences, I-Mab, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Provention Bio, Sandoz\/Hexal, Takeda, Theravance Biopharma, and UCB. A.J.W. reports personal fees from AbbVie, Alfasigma, Bristol Myers Squibb, Dr. Falk Pharma, Eli Lilly and Company, Ferring, Galapagos, GlaxoSmithKline, Janssen, Pfizer, Sandoz, and Takeda. T.H. reports lecture fees from AbbVie, Ferring, Gilead Sciences, Janssen, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Miyarisan Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Takeda, and Zeria Pharmaceutical; advisory\/consultancy fees from EA Pharma, Eli Lilly and Company, Janssen, Mitsubishi Tanabe Pharma, Pfizer, Takeda, and Zeria Pharmaceutical; and research grants from AbbVie, JIMRO, and Zeria Pharmaceutical. S.P.L.T. reports grants\/research support from AbbVie, Buhlmann, Celgene, Eli Lilly and Company, IOIBD, Janssen, Norman Collisson Foundation, Pfizer, Takeda, UCB, and Vifor; consulting fees from Abacus Pharma, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Aptel, Arena Pharmaceuticals, Asahi Kasei Pharma Corporation, Aspen Pharmacare, Astellas Pharma, AstraZeneca, Atlantic Pharma, Barco, Biocare, Biogen, BL Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Buhlmann, Calico, Celgene, Cellerix, Cerimon Pharmaceuticals, ChemoCentryx, Chiesi, Cisbio, Comcast, Coronado Biosciences, Cosmo, Ducentis BioTherapeutics, Dr. Falk Pharma, Dynavax Technologies, Elan Pharmaceuticals, Eli Lilly and Company, Enterome, Ferring, FPRT Bio, Galapagos, Genentech\/Roche, Genzyme, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Gr\u00fcnenthal, GW Pharmaceuticals, Immunocore, Indigo, Janssen, Lexicon Pharmaceuticals, Medarex, Medtrix, Merck, Merrimack Pharmaceuticals, Millenium Pharmaceuticals, Neovacs, Novartis, Novo Nordisk, NPS Pharmaceuticals\/Nycomed, Ocera Therapeutics, Optima Pharma, Origin, Otsuka Pharmaceutical, Palau Pharma, Pentax Medical, Pfizer, PharmaVentures, Philips, Procter & Gamble, Pronota, Proximagen, Resolute Therapeutics, Robarts, Sandoz, Santarus, Satisfai Health, Sensyne Health, Shire, Sigmoid Pharma, Souffinez, Sun Pharma, SynDermix, Synthon, Takeda, Theravance Biopharma, TiGenix, Tillotts, TopiVert Pharma, Trino Therapeutics with Wellcome Trust, TxCell, UCB, Vertex Pharmaceuticals, VHsquared, Vifor, Warner Chilcott, and Zeria Pharmaceutical; and speaker fees from AbbVie, Amgen, Biogen, Dr. Falk Pharma, Ferring, Janssen, Pfizer, Shire, Takeda, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}